Jack Phillips Sells 26,735 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,735 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $0.78, for a total value of $20,853.30. Following the transaction, the chief executive officer now owns 162,919 shares in the company, valued at approximately $127,076.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Phillips also recently made the following trade(s):

• On Friday, April 12th, Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.86, for a total value of $22,828.70.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.88, for a total value of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $1.30, for a total value of $642.20.

Accelerate Diagnostics Stock Performance

Shares of Accelerate Diagnostics stock opened at $0.86 on Friday. The business’s 50 day simple moving average is $0.99 and its 200 day simple moving average is $3.16. Accelerate Diagnostics, Inc. has a 52-week low of $0.73 and a 52-week high of $11.90. The firm has a market cap of $18.61 million, a PE ratio of -0.18 and a beta of 0.52.

Analyst Upgrades and Downgrades

AXDX has been the topic of several recent analyst reports. Craig Hallum cut their price objective on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a report on Monday, April 1st. StockNews.com initiated coverage on Accelerate Diagnostics in a report on Saturday. They set a “hold” rating on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd.

Institutional Investors Weigh In On Accelerate Diagnostics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC raised its position in Accelerate Diagnostics by 95.4% in the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after buying an additional 17,461 shares during the last quarter. Bank of Montreal Can acquired a new stake in Accelerate Diagnostics in the 1st quarter valued at approximately $27,000. Cubist Systematic Strategies LLC acquired a new stake in Accelerate Diagnostics in the 3rd quarter valued at approximately $29,000. Bank of America Corp DE raised its position in Accelerate Diagnostics by 110.7% in the 4th quarter. Bank of America Corp DE now owns 42,395 shares of the medical research company’s stock valued at $30,000 after buying an additional 22,273 shares during the last quarter. Finally, UBS Group AG raised its position in Accelerate Diagnostics by 6,250.0% in the 1st quarter. UBS Group AG now owns 50,800 shares of the medical research company’s stock valued at $36,000 after buying an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.